{
  "model": "chatgpt-gpt-5.3-codex",
  "agentReasoning": "medium",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 1,
  "workspacePath": "workspaces/chatgpt-gpt-5-3-codex-tumor-vaccine-ici-run-1",
  "success": true,
  "schemaPass": true,
  "toolTracePass": true,
  "graderPass": true,
  "durationMs": 63581,
  "agentCostUsd": 0.059453750000000014,
  "graderCostUsd": 0.013452249999999999,
  "totalCostUsd": 0.07290600000000001,
  "agentUsage": {
    "promptTokens": 18299,
    "cachedTokens": 0,
    "responseTokens": 3418,
    "thinkingTokens": 240,
    "totalTokens": 21957
  },
  "graderUsage": {
    "promptTokens": 4071,
    "cachedTokens": 0,
    "responseTokens": 168,
    "thinkingTokens": 284,
    "totalTokens": 4523
  },
  "totalUsage": {
    "promptTokens": 22370,
    "cachedTokens": 0,
    "responseTokens": 3586,
    "thinkingTokens": 524,
    "totalTokens": 26480
  },
  "modelVersions": [
    "chatgpt-gpt-5.3-codex"
  ],
  "agentFinalText": "- [x] `output/study_overview.json`\n- [x] `output/quantitative_findings.json`\n- [x] `output/claim_audit.json`\n- [x] `output/public_summary.json`",
  "outputValidation": [
    {
      "outputFile": "output/study_overview.json",
      "schemaFile": "schemas/study_overview.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Whether intratumoral mRNA vaccination can induce an interferon-rich tumor state that improves response to anti-PD-L1 immune checkpoint blockade.\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-cohort\",\n      \"label\": \"Mouse efficacy cohort (combination therapy)\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n      \"description\": \"Pooled repeat experiments testing combined intratumoral mRNA vaccine plus anti-PD-L1 treatment in murine tumor models.\"\n    },\n    {\n      \"id\": \"mouse-control-cohort\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n      \"description\": \"Matched controls included vaccine-only, ICI-only, and vehicle conditions to benchmark whether combination effects exceeded single-agent activity.\"\n    },\n    {\n      \"id\": \"human-retrospective-metastatic\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients total\",\n      \"description\": \"Retrospective analysis of metastatic patients receiving ICI, stratified by prior SARS-CoV-2 mRNA vaccination status.\"\n    },\n    {\n      \"id\": \"human-vaccinated-subgroup\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subset of the retrospective metastatic cohort with prior mRNA vaccination before or around ICI treatment.\"\n    },\n    {\n      \"id\": \"human-unvaccinated-subgroup\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Subset of the retrospective metastatic cohort without prior SARS-CoV-2 mRNA vaccination for comparison of survival outcomes.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized, so residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across settings.\"\n  ]\n}"
    },
    {
      "outputFile": "output/quantitative_findings.json",
      "schemaFile": "schemas/quantitative_findings.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3% comparator\",\n      \"interpretation\": \"Intratumoral mRNA vaccination was associated with broader antigen display.\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6% comparator\",\n      \"interpretation\": \"The MHC-I-presented peptide landscape expanded strongly after vaccination.\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"vaccinated subgroup vs unvaccinated subgroup under ICI\",\n      \"interpretation\": \"The vaccinated subgroup showed a statistically significant survival association.\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0 baseline\",\n      \"interpretation\": \"Tumors showed marked induction of type I interferon signaling after mRNA vaccination.\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x baseline\",\n      \"interpretation\": \"Checkpoint pathway activity increased, supporting rationale for anti-PD-L1 combination.\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x baseline\",\n      \"interpretation\": \"Combination therapy increased immune-cell infiltration within tumors.\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking IFNAR1 signaling eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/claim_audit.json",
      "schemaFile": "schemas/claim_audit.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination broadens tumor antigen presentation, including MHC-I peptide display.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\",\n          \"line_ref\": \"L29\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"mRNA vaccination induces a type I interferon-rich tumor state linked to sensitization.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\n          \"line_ref\": \"L31\"\n        },\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors, limiting direct clinical extrapolation.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"The combination rationale is supported by increased PD-L1 axis activity and improved mouse tumor control context.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable\",\n          \"line_ref\": \"L32\"\n        },\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        }\n      ],\n      \"caveat\": \"Vaccine-only and ICI-only arms showed limited durability/activity in some settings, so benefit depends on context and combination design.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Prior SARS-CoV-2 mRNA vaccination is associated with better survival among metastatic patients treated with ICI.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n          \"line_ref\": \"L49\"\n        }\n      ],\n      \"caveat\": \"Because patient groups were non-randomized and clinically heterogeneous, this association should not be interpreted as definitive causality.\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/public_summary.json",
      "schemaFile": "schemas/public_summary.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"headline\": \"mRNA vaccination inside tumors may make checkpoint therapy work better, but proof in trials is still needed\",\n  \"plain_language_summary\": \"This study tested whether putting an mRNA vaccine directly into tumors can help immune checkpoint drugs work in cancers that are otherwise hard to treat. In mouse experiments, the vaccine plus anti-PD-L1 therapy outperformed single-treatment controls and was linked to stronger immune activation inside tumors. The authors report more tumor peptides displayed to immune cells, higher type I interferon signaling, increased PD-L1 expression, and greater CD8+ T-cell infiltration. In a separate retrospective analysis of 130 metastatic patients receiving checkpoint inhibitors, people with prior SARS-CoV-2 mRNA vaccination had better survival statistics (p=0.01). Together, these findings support a plausible biological mechanism and a clinically relevant hypothesis. However, the human data are observational, not randomized, and include variable timing and mixed tumor histories, so the work supports promise rather than clinical proof.\",\n  \"what_is_new\": [\n    \"The paper links intratumoral mRNA vaccination to broader antigen presentation and expanded MHC-I peptidomes in tumors.\",\n    \"It connects interferon pathway activation to checkpoint sensitization using perturbation controls such as IFNAR1 blockade.\",\n    \"It bridges mouse mechanism data with a human retrospective ICI cohort stratified by prior mRNA vaccination status.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human cohort is retrospective and non-randomized, leaving substantial risk of residual confounding.\",\n    \"Vaccination timing relative to checkpoint treatment varied, which can bias apparent outcome differences.\",\n    \"Tumor-type and treatment-history heterogeneity limit clean causal interpretation across all patients.\",\n    \"Effects seen in selected mouse models may not generalize to every human cancer context.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune checkpoint inhibitor (ICI)\",\n      \"definition\": \"A cancer drug that releases inhibitory brakes on T cells, helping the immune system attack tumors more effectively.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein used by tumors to suppress immune attack; blocking the PD-1/PD-L1 pathway can restore T-cell activity.\"\n    },\n    {\n      \"term\": \"MHC-I peptidome\",\n      \"definition\": \"The set of peptide fragments displayed on MHC class I molecules that informs T cells which cells appear abnormal.\"\n    },\n    {\n      \"term\": \"Type I interferon signaling\",\n      \"definition\": \"An innate immune response program that can increase antigen processing and improve anti-tumor immune priming.\"\n    },\n    {\n      \"term\": \"Retrospective cohort\",\n      \"definition\": \"A study design that looks back at existing patient data rather than assigning treatments prospectively at random.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Will randomized prospective trials confirm that this strategy improves survival beyond standard checkpoint therapy?\",\n    \"Which tumor types and baseline immune states are most likely to benefit from intratumoral mRNA sensitization?\",\n    \"What vaccination timing and dosing schedule relative to ICI produces the strongest and safest effect?\",\n    \"Can biomarkers such as interferon scores or peptidome expansion predict which patients will respond?\"\n  ]\n}"
    }
  ],
  "toolTrace": {
    "pass": true,
    "totalCalls": 24,
    "failedCalls": 0,
    "toolsUsed": [
      "glob",
      "list_directory",
      "read_file",
      "write_file"
    ],
    "hasSuccessfulRead": true,
    "hasSuccessfulWrite": true,
    "pathPolicyViolations": [],
    "notes": [],
    "calls": [
      {
        "source": "llm",
        "step": 1,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "glob"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 5,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 5,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 5,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 5,
        "toolName": "write_file"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "TASK.md",
        "timestamp": "2026-02-13T15:11:47.715Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": ".",
        "timestamp": "2026-02-13T15:11:49.579Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "input/report.md",
        "timestamp": "2026-02-13T15:11:51.215Z"
      },
      {
        "source": "fs",
        "toolName": "glob",
        "action": "search",
        "path": "schemas",
        "timestamp": "2026-02-13T15:11:51.216Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/study_overview.schema.json",
        "timestamp": "2026-02-13T15:11:53.570Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/quantitative_findings.schema.json",
        "timestamp": "2026-02-13T15:11:53.570Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/claim_audit.schema.json",
        "timestamp": "2026-02-13T15:11:53.571Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/public_summary.schema.json",
        "timestamp": "2026-02-13T15:11:53.571Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/study_overview.json",
        "timestamp": "2026-02-13T15:12:35.478Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-13T15:12:35.478Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-13T15:12:35.478Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-13T15:12:35.478Z"
      }
    ]
  },
  "grader": {
    "model": "chatgpt-gpt-5.2",
    "value": {
      "verdict": "pass",
      "scores": {
        "faithfulness": 5,
        "coverage": 5,
        "usefulness": 5
      },
      "critical_issues": [],
      "summary": "All provided JSON files are consistent with the numbered report lines and do not introduce fabricated quantitative values or unsupported causal claims. Key quantitative results (immunopeptidome expansion, MHC-I expansion, IFN score, PD-L1 fold-change, CD8 density change, and human retrospective p-value) are correctly reproduced with valid line references (L28â€“L33). Core controls and conditional/negative results (vaccine-only limitations, ICI-only limitations, lipid particle control, and IFNAR1 ("
    }
  }
}
